PBE Invesco Biotechnology & Geno Funds
- 62.860
- +1.988+3.27%
Fed, Earnings Outlooks Lift Wall Street Pre-Bell; Asia Mixed, Europe Off
Wall Street futures pointed moderately higher pre-bell Thursday after Federal Reserve Chair Jerome Powell on Wednesday appeared to rule out rate hikes for 2024, and following disclosures that the cent
Neurocrine Price Target Raised to $160.00/Share From $150.00 by HC Wainwright & Co.
Neurocrine Price Target Raised to $160.00/Share From $150.00 by HC Wainwright & Co.
Bio-Techne Is Maintained at Outperform by Baird
Bio-Techne Is Maintained at Outperform by Baird
HC Wainwright & Co. : The Neurocrine Biosciences (NBIX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $150.00 to $160.00.
HC Wainwright & Co. : The Neurocrine Biosciences (NBIX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $150.00 to $160.00.
Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market
U.S. stocks look to push ahead on a positive path, now that the Federal Reserve's rate decision is in the rearview mirror. Major index futures point to a positive open on Thursday. Pent-up demand foll
Baird Maintains Outperform on Bio-Techne, Raises Price Target to $81
Baird analyst Catherine Schulte maintains Bio-Techne (NASDAQ:TECH) with a Outperform and raises the price target from $73 to $81.
Bio-Techne Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 10.26% Baird $73 → $81 Maintains Outperform 04/18/2024 11.63% Deutsche Bank $85 → $82 Maintains
Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales
By Denny Jacob Regeneron Pharmaceuticals posted lower-than-expected revenue in its latest quarter which resulted in part from lower sales of EYLEA in the U.S. The biotechnology company recorded net
Regeneron's Stock Dips After Earnings Fall Short of Estimates
Regeneron Pharmaceuticals Inc.'s stock (REGN) fell 3% early Thursday, after the company's first-quarter earnings fell short of estimates. The company had net income of $722 million, or $6.27 a share,
UPDATE 2-Regeneron Misses Profit Estimates on Weaker Eylea and Dupixent Sales
Earnings Flash (REGN) REGENERON PHARMACEUTICALS Reports Q1 Revenue $3.15B, Vs. Street Est of $3.22B
06:34 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (REGN) REGENERON PHARMACEUTICALS Reports Q1 Revenue $3.15B, vs. Street Est of $3.22B
Regeneron Pharma Still Sees 2024 Adjusted Gross Margin 89%-91% >REGN
Regeneron Pharma Still Sees 2024 Adjusted Gross Margin 89%-91% >REGN
Regeneron Pharma Cuts 2024 Capital Spending View to $780M-$880M From $825M-$950M >REGN
Regeneron Pharma Cuts 2024 Capital Spending View to $780M-$880M From $825M-$950M >REGN
Regeneron Pharma Sets New $3 Billion Share-Repurchase Program >REGN
Regeneron Pharma Sets New $3 Billion Share-Repurchase Program >REGN
Press Release: Regeneron Reports First Quarter 2024 Financial and Operating Results
Regeneron Reports First Quarter 2024 Financial and Operating Results -- First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), reve
Regeneron Pharma 1Q Adj EPS $9.55 >REGN
Regeneron Pharma 1Q Adj EPS $9.55 >REGN
Needham Reiterates Hold on Neurocrine Biosciences
Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Hold.
Carvana, Fastly, Qualcomm, DoorDash, Zillow, Etsy, Freshworks, Apple, and More Stock Market Movers
Carvana posts a surprise first-quarter profit, while Fastly stock sinks after the company issues guidance well below Wall Street estimates. Apple is scheduled to report fiscal second-quarter earnings after the closing bell Thursday.
KeyBanc Remains a Buy on Bio-Techne (TECH)
Analysts Offer Insights on Healthcare Companies: Bio-Techne (TECH) and Amneal Pharmaceuticals (AMRX)